Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.

The Advent and ideation

Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.

Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.

“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.

No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.

FDA's Role in the Push

The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.

Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.

What Could Be The Challenges?

Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.

Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.

Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.

Could Low-Nicotine Cigarettes Be The Solution?

Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.

Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.

Cancer care has evolved significantly over the last few decades. Today, success is measured not only by survival rates but also by quality of life, emotional well-being, and the ability to return to a regular life after treatment. Yet, in our pursuit of patient-centered care, an essential component often remains invisible: caregivers.

Every cancer diagnosis affects more than just the patient. Behind every woman navigating treatment is often a spouse, parent, sibling, child, or friend who assumes the role of caregiver. They accompany patients to appointments, help manage treatment schedules, provide emotional reassurance, and often become the primary support system through one of life's most challenging experiences.

Why Caregivers Need Support

Despite their indispensable role, caregivers frequently receive little formal support themselves.

As oncologists, we witness this every day. We see caregivers putting their own health, careers, and emotional needs on hold to care for a loved one. While patients are understandably at the center of treatment, caregivers often carry an immense psychological and physical burden that goes unrecognized.

Through years of clinical practice, I have come to understand that caregivers are not merely bystanders in the cancer journey; they are active partners in healing. Yet, many families find themselves navigating unfamiliar territory with little guidance on what to expect, how to cope, or where to seek support.

The guide was conceived as a practical, step-by-step resource to help caregivers navigate different stages of the cancer journey from diagnosis and treatment to recovery and survivorship. More importantly, it acknowledges their resilience, fears, sacrifices, and emotional struggles, while equipping them with the information and support needed to care for both their loved ones and themselves.

Cancer Survivorship Is a Shared Journey

Cancer survivorship does not begin when treatment ends; it begins when patients and families start rebuilding their lives after cancer. Survivors may continue to face concerns around recurrence, fertility, body image, relationships, mental health, and long-term treatment effects. Caregivers, too, often carry lingering anxiety, exhaustion, and emotional trauma long after active treatment is over.

If we truly want to improve survivorship outcomes, caregiver support must become a standard component of oncology care rather than an afterthought.

This support can take many forms. It may include counselling services, support groups, educational resources, survivorship planning sessions, and opportunities for caregivers to openly discuss their own concerns. Equally important is creating healthcare environments where caregivers feel seen, heard, and included in care conversations.

Moving Towards Holistic Cancer Care

It is about time cancer care should move beyond a disease-centered approach towards a more holistic understanding of survivorship. While medical treatment remains central, there is growing recognition that recovery is also shaped by emotional well-being, family support systems, fertility concerns, body image, nutrition, rehabilitation, and quality of life after treatment.

This broader view of cancer care requires us to look beyond the patient alone. Caregivers are often the invisible backbone of the treatment journey, yet their needs frequently go unaddressed. As healthcare professionals, we must acknowledge that supporting caregivers is not separate from supporting patients. It is an integral part of comprehensive cancer care and long-term survivorship.

Caring Beyond Cure

As healthcare systems continue to advance, we must expand our understanding of what comprehensive cancer care looks like. A patient cannot thrive in isolation. When caregivers are empowered, informed, and emotionally supported, patient outcomes improve and survivorship becomes more sustainable for everyone involved.

Cancer survivorship is not an individual journey. It is a shared experience of resilience, hope, and recovery. By recognizing caregivers as integral members of the care team and providing them with the support they need, we move one step closer to a more humane and holistic model of oncology care, one that truly cares beyond cure.

(Dr. Jyoti Wadhwa, Principal Lead, Medical & Precision Oncology, Apollo Athenaa Women's Centre)

Longevity expert and millionaire Bryan Johnson has revealed that he has been diagnosed with autoimmune gastritis (AIG), a condition in which the immune system attacks the stomach lining.

In a post on X, Johnson, known for his radical experiments, including receiving blood transfusions from his teenage son, said he believes years of eating sugary cereals, drinking soda, consuming fast food and experiencing chronic stress contributed to the development of his autoimmune conditions.

Calling it a "bad news", the millionaire said: "I have an autoimmune disease. My stomach is eating itself". He added that "2–5% of people have this, too. Likely more, because it hides".

“As a kid, I ate sugar cereal, drank sugary soda, and gobbled down fast food. I had a few healthy years in my early 20s, but then became a young father of three and began building a business. Juggling that stress and grind, I let my health slip and gained 40 lbs,” he wrote.

He added that he later developed chronic depression and believes that during this period, his body began an autoimmune process affecting both his thyroid and stomach lining.

Also read: Donald Trump Posts AI Video of Himself Treating Critics for 'Derangement Syndrome'

Diagnosed With Hypothyroidism At 21

Johnson said he was diagnosed with hypothyroidism at the age of 21 during a routine blood test. He has since managed the condition with levothyroxine and Armour Thyroid.

“They are the hormones my body should be producing on its own, but wasn’t. By taking these pills daily, my body was able to operate as though my thyroid was functioning properly.”

He said his stomach had also begun attacking itself, but the condition went undetected because he had no symptoms. It was only discovered in May.

Johnson noted that autoimmune gastritis can cause irreversible damage, including nutritional deficiencies, anemia, and an increased long-term risk of stomach cancer.

Early Signs

Read More: Why Fentanyl Addiction Treatments Are Losing Effectiveness, Study Finds

Johnson said he had persistently low ferritin levels for the past 11 years despite not having anemia.

“We continually tried to raise my iron levels with food and supplementation, but nothing would work.”

He said he followed a plant-based diet, trained intensely, used a sauna and hyperbaric oxygen therapy, and took iron supplements, but his iron levels remained low.

A colonoscopy ruled out slow gastrointestinal bleeding, while an upper endoscopy with five stomach biopsies revealed early autoimmune gastritis. The biopsies showed early atrophy confined to the stomach's acid-producing lining, while

the rest of the stomach remained unaffected.

“So this was never one problem. It was three, linked to one another: the iron deficiency, the autoimmune gastritis driving it, and the autoimmune thyroid disease alongside it.”

Bryan Johnson's Treatment Plan

Johnson said he has undergone a large blood draw to sequence more than one million individual immune cells.

According to him, the goal is to identify the specific immune cell clones attacking his stomach lining. He compared immune cells to soldiers carrying unique "keys," explaining that the advanced sequencing technology can identify the rogue immune cells responsible for autoimmune gastritis.

Johnson said that once those immune cells are identified, the findings will help determine the most appropriate therapy to target and suppress the autoimmune attack.

What Is Autoimmune Gastritis?

Autoimmune gastritis (AIG) is a long-term autoimmune disorder in which the body's immune system mistakenly attacks the stomach's parietal cells, which produce stomach acid, as well as intrinsic factor, a protein essential for absorbing vitamin B12. Over time, this damages the stomach lining and reduces the body's ability to absorb iron and vitamin B12, increasing the risk of nutrient deficiencies.

In many people, symptoms are caused more by these nutritional deficiencies than by inflammation of the stomach itself.

Common symptoms include:

• Ongoing fatigue and weakness
• Low iron levels or iron-deficiency anemia
• Vitamin B12 deficiency, which may lead to numbness, tingling, balance problems or memory difficulties
• Pale skin and shortness of breath
• Reduced appetite, bloating, nausea or discomfort in the upper abdomen
• Mouth ulcers.

The Ebola outbreak in DR Congo has risen to 1,427 cases, while the death toll has climbed to 440, according to the latest government data.

More than 609 patients are hospitalized in Congo, while many have also recovered. Uganda has so far reported 20 confirmed cases and two deaths. There has also been one case in France and another in a US citizen medically evacuated to Germany, both believed to have been imported from areas affected by the ongoing outbreak.

The Ebola virus disease, caused by the Bundibugyo strain, has no approved vaccine or treatment.

"Even without approved therapeutics, people are recovering from this disease, but, of course, we could save many more lives with safe and effective therapeutics in our toolkit," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

He said this while announcing the launch of the clinical trial of two therapeutics, with the enrolment of the first patient.

"The PARTNERS trial will evaluate the monoclonal antibody MBP134 and the antiviral drug remdesivir, alone and in combination," he added.

Also read: Donald Trump Posts AI Video of Himself Treating Critics for 'Derangement Syndrome'

All About the Trial

The study is being coordinated by the DRC's National Institute for Biomedical Research, supported by a coalition of partners including WHO, and conducted in close cooperation with the affected communities.

According to Tedros, patients who enroll in the trial will receive comprehensive supportive care and close follow-up.

"We are also working to ensure they have access to the two drugs should they prove safe and efficacious in the trial."

In addition, the WHO has granted emergency use listing to the first molecular diagnostic test for Bundibugyo virus.

Further, the antiviral drug remdesivir, marketed as Veklury is also expected to start. Remdesivir became widely known during the COVID-19 pandemic and is being evaluated to determine whether it can improve outcomes when combined with the antibody treatment.

As per experts, it could take months, and possibly as many as 1,000 study participants, to determine whether either drug works.

Currently, the study is being offered only at one Ebola treatment center in Congo's Ituri province. The region has been heavily affected by violence, including attacks on healthcare workers responding to a virus spread through contact with infected patients' bodily fluids. Officials plan to expand the trial to other locations once it is safe to do so.

Read More: Australia Reports More H5 Bird Flu Cases: Does It Have Pandemic Potential?

Challenges Remain

Tedros said that despite the progress, significant challenges remain, including mistrust and violence.

This week, an Ebola treatment center in Ituri province was attacked, resulting in the deaths of two people. The center was set on fire, and patients fled.

Such acts not only endanger patients and health workers but also impede efforts to stop transmission and save lives.

He added that the complexity of the outbreak requires close coordination across the United Nations system.

What Is Ebola?

Ebola is a severe and often fatal viral hemorrhagic fever first identified in 1976. Since then, more than 30 outbreaks have been recorded, primarily in Central and West Africa.

Common Symptoms of Ebola

• Fever
• Headache
• Weakness and fatigue
• Vomiting
• Diarrhea
• Muscle pain
• Sore throat
• Unexplained bleeding or bruising.